Allergy Therapeutics PLC Block Listing Interim Review
December 17 2024 - 10:19AM
RNS Regulatory News
RNS Number : 4634Q
Allergy Therapeutics PLC
17 December 2024
Allergy Therapeutics
plc
("Allergy
Therapeutics", "ATL" or the "Group")
Block Listing Interim
Review
|
Name of applicant:
|
ALLERGY THERAPEUTICS PLC
|
|
Name of scheme:
|
Allergy Therapeutics plc 2013 Long
Term Incentive Plan
|
|
Period of return:
|
From:
|
1 October 2023
|
To:
|
17 December 2024
|
|
Number and class of share(s) (amount
of stock / debt securities) originally listed and the date of
admission:
|
10,000,000 ordinary shares of 0.1p
each in the Company admitted to trading on 24 November
2017
Additional listing of 7,000,000
ordinary shares of 0.1p each in the Company admitted to trading on
7 April 2021
Additional listing of 5,000,000
ordinary shares of 0.1p each in the Company admitted to trading on
3 October 2023
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
12,013,147 ordinary
shares
|
|
Plus: The amount by which the block scheme(s) has been increased
since the date of the last return (if any increase has been applied
for):
|
|
|
Less: Number of securities issued/allotted under
scheme(s) during period:
|
12,013,147 ordinary shares of 0.1p
each
|
|
Equals: Balance under scheme(s) not yet issued/allotted at end of
period:
|
Nil
|
|
|
|
|
|
|
|
Name of contact:
|
Karley Cheesman
|
|
Telephone number of
contact:
|
+44 (0) 1903 844 700
|
For
further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science Specialist
Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR
Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see
www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLREAKAXFFELFFA
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Dec 2023 to Dec 2024
